Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis
- PMID: 2906477
- DOI: 10.3109/00365528809101547
Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis
Abstract
Olsalazine and sulphasalazine were compared in a double-blind, double-dummy trial in the prevention of relapse of ulcerative colitis over 6 months. The majority were taking sulphasalazine. They were randomized to receive either olsalazine, 500 mg b.d., or sulphasalazine, 1 g b.d. Of 82 patients, 16 relapsed on olsalazine compared with 10 of 82 on sulphasalazine. This difference was not statistically significant (p = 0.16). Twenty-one patients reported adverse events in the olsalazine group, of whom 16 were withdrawn, while 20 patients reported adverse events in the sulphasalazine group, with 9 of them being withdrawn. The differences were not statistically significant. No major haematological or biochemical abnormalities occurred. Thus, olsalazine is similar to sulphasalazine for the prevention of relapse of ulcerative colitis.
Similar articles
-
Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.Gut. 1988 Jun;29(6):835-7. doi: 10.1136/gut.29.6.835. Gut. 1988. PMID: 2898422 Free PMC article. Clinical Trial.
-
Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.Scand J Gastroenterol Suppl. 1988;148:70-5. doi: 10.3109/00365528809101553. Scand J Gastroenterol Suppl. 1988. PMID: 2906479 Clinical Trial.
-
Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.Gut. 1992 Feb;33(2):252-5. doi: 10.1136/gut.33.2.252. Gut. 1992. PMID: 1347280 Free PMC article. Clinical Trial.
-
Evolution of olsalazine.Scand J Gastroenterol Suppl. 1988;148:3-6. doi: 10.3109/00365528809101538. Scand J Gastroenterol Suppl. 1988. PMID: 2906475 Review.
-
Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.Clin Pharm. 1992 Jun;11(6):514-28. Clin Pharm. 1992. PMID: 1600685 Review.
Cited by
-
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev. 2016 May 9;2016(5):CD000544. doi: 10.1002/14651858.CD000544.pub4. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Aug 28;8:CD000544. doi: 10.1002/14651858.CD000544.pub5. PMID: 27158764 Free PMC article. Updated.
-
Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial.Gut. 1989 Oct;30(10):1354-61. doi: 10.1136/gut.30.10.1354. Gut. 1989. PMID: 2684804 Free PMC article. Clinical Trial.
-
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev. 2020 Aug 28;8(8):CD000544. doi: 10.1002/14651858.CD000544.pub5. Cochrane Database Syst Rev. 2020. PMID: 32856298 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical